Published By : 25 Nov 2015 | Published By : QYRESEARCH
Xellia Pharmaceuticals has recently entered into a contract with Hikma Pharmaceuticals, according to which the former gets the acquisition of Hikma owned production units in Bedford, Ohio. Denmark-based Xellia Pharma is a specialty pharmaceutical firm, which focuses on providing significant anti-infective treatments against serious infections.
According to the agreement, the pharma company has acquired significant portions of the site along with several new production facilities for sterile injectables. These units are not in operation as of now. Hikma will be holding the remaining facilities the also includes the Quality and Development Center, operated by West-Ward Injectables Inc. a subsidiary of Hikma.
Previous to this, Ben Venue Laboratories Inc. owned the site and ceased production in December 2013. Xellia Pharma has planned to invest a significant amount in the production units to resume the manufacturing procedures at the site as well as in the establishment. The training of a new enterprise, who will operate the plant, is also on the cards. The firm has stated that it will work closely with the U.S. FDA, ensuring a controlled and timely start-up at the plant.
The pharma company plans to initiate commercial production within 2 years at the site. The plant will function along with the existing production plant of Xellia for sterile injectables in Raleigh, North Carolina.
Mr. Carl-Åke Carlsson, the CEO, Xellia has stated that the U.S. is an extremely important market for them. The country has a robust production heritage in the pharmaceutical industry and possesses a huge base of a skilled and specialized workforce, and hence, the country will prove to be the ideal location for the expansion of their manufacturing capabilities.